Comparison of first-line and second-line use of fingolimod in relapsing MS: The open-label EARLIMS study
暂无分享,去创建一个
H. Butzkueven | M. Barnett | G. Izquierdo | Diego G. Silva | C. Ramo | E. Aguera | M. Hernández | Ó. Fernández | R. Walker | Chenyu Wang